{"id":"https://openalex.org/W2168183167","doi":"https://doi.org/10.1158/1078-0432.ccr-07-1475","title":"Population Pharmacokinetic-Pharmacodynamic Model of the Vascular-Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid in Cancer Patients","display_name":"Population Pharmacokinetic-Pharmacodynamic Model of the Vascular-Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid in Cancer Patients","publication_year":2008,"publication_date":"2008-04-01","ids":{"openalex":"https://openalex.org/W2168183167","doi":"https://doi.org/10.1158/1078-0432.ccr-07-1475","mag":"2168183167","pmid":"https://pubmed.ncbi.nlm.nih.gov/18381951"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-07-1475","doi":"https://doi.org/10.1158/1078-0432.ccr-07-1475","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-07-1475","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100336946","display_name":"Jing Li","orcid":"https://orcid.org/0000-0002-5381-4716","observed_orcids":["https://orcid.org/0000-0002-5381-4716"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I4210164401","display_name":"Sidney Kimmel Comprehensive Cancer Center","ror":"https://ror.org/05m5b8x20","country_code":"US","type":"facility","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jing Li","raw_affiliation_strings":["1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland;","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I4210164401"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000993397","display_name":"Michael B. Jameson","orcid":"https://orcid.org/0000-0001-7068-4311","observed_orcids":["https://orcid.org/0000-0001-7068-4311"]},"institutions":[{"id":"https://openalex.org/I2801645848","display_name":"Waikato Hospital","ror":"https://ror.org/002zf4a56","country_code":"NZ","type":"healthcare","lineage":["https://openalex.org/I2801645848","https://openalex.org/I4405259026"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"Michael B. Jameson","raw_affiliation_strings":["2Waikato Hospital, Hamilton, New Zealand; and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Waikato Hospital, Hamilton, New Zealand; and","institution_ids":["https://openalex.org/I2801645848"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061684371","display_name":"Bruce C. Baguley","orcid":"https://orcid.org/0000-0001-9943-6987","observed_orcids":["https://orcid.org/0000-0001-9943-6987"]},"institutions":[{"id":"https://openalex.org/I154130895","display_name":"University of Auckland","ror":"https://ror.org/03b94tp07","country_code":"NZ","type":"education","lineage":["https://openalex.org/I154130895"]}],"countries":["NZ"],"is_corresponding":false,"raw_author_name":"Bruce C. Baguley","raw_affiliation_strings":["3Auckland Cancer Society Research Center, University of Auckland, Auckland, New Zealand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Auckland Cancer Society Research Center, University of Auckland, Auckland, New Zealand","institution_ids":["https://openalex.org/I154130895"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003107448","display_name":"\u0420\u043e\u0431\u0435\u0440\u0442\u043e \u041f\u0438\u043b\u0438","orcid":"https://orcid.org/0009-0004-9993-9911","observed_orcids":["https://orcid.org/0009-0004-9993-9911","https://orcid.org/0000-0002-5871-4896"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I4210164401","display_name":"Sidney Kimmel Comprehensive Cancer Center","ror":"https://ror.org/05m5b8x20","country_code":"US","type":"facility","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roberto Pili","raw_affiliation_strings":["1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland;","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I4210164401"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5077260725","display_name":"Sharyn D. Baker","orcid":"https://orcid.org/0000-0003-3062-3252","observed_orcids":["https://orcid.org/0000-0003-3062-3252"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I4210164401","display_name":"Sidney Kimmel Comprehensive Cancer Center","ror":"https://ror.org/05m5b8x20","country_code":"US","type":"facility","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sharyn D. Baker","raw_affiliation_strings":["1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland;","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I4210164401"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.233,"has_fulltext":false,"cited_by_count":20,"citation_normalized_percentile":{"value":0.78051786,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"14","issue":"7","first_page":"2102","last_page":"2110"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.5781000256538391,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.5781000256538391,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.10170000046491623,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.06960000097751617,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dmxaa","display_name":"DMXAA","score":0.9589999914169312},{"id":"https://openalex.org/keywords/vascular-disrupting-agents","display_name":"vascular disrupting agents","score":0.7350000143051147},{"id":"https://openalex.org/keywords/population-pharmacokinetic-pharmacodynamic-model","display_name":"population pharmacokinetic/pharmacodynamic model","score":0.859000027179718},{"id":"https://openalex.org/keywords/5-hydroxyindoleacetic-acid","display_name":"5-hydroxyindoleacetic acid","score":0.9739999771118164},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.5740000009536743},{"id":"https://openalex.org/keywords/michaelis-menten-elimination","display_name":"Michaelis-Menten elimination","score":0.8450000286102295},{"id":"https://openalex.org/keywords/saturable-elimination","display_name":"saturable elimination","score":0.718999981880188},{"id":"https://openalex.org/keywords/sex-differences","display_name":"sex differences","score":0.6579999923706055},{"id":"https://openalex.org/keywords/volume-of-distribution","display_name":"volume of distribution","score":0.7670000195503235},{"id":"https://openalex.org/keywords/antivascular-effects","display_name":"antivascular effects","score":0.7720000147819519},{"id":"https://openalex.org/keywords/dose-selection","display_name":"dose selection","score":0.5289999842643738},{"id":"https://openalex.org/keywords/nonlinear-mixed-effects-models","display_name":"nonlinear mixed-effects models","score":0.7250000238418579}],"concepts":[{"id":"https://openalex.org/C2776239304","wikidata":"https://www.wikidata.org/wiki/Q6954915","display_name":"NONMEM","level":3,"score":0.8058438897132874},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7842796444892883},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.6707186698913574},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6385159492492676},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5221236348152161},{"id":"https://openalex.org/C139254425","wikidata":"https://www.wikidata.org/wiki/Q1332167","display_name":"Volume of distribution","level":3,"score":0.4816704988479614},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.47477126121520996},{"id":"https://openalex.org/C96529984","wikidata":"https://www.wikidata.org/wiki/Q286136","display_name":"EC50","level":3,"score":0.46900343894958496},{"id":"https://openalex.org/C2776673659","wikidata":"https://www.wikidata.org/wiki/Q47512","display_name":"Acetic acid","level":2,"score":0.4289637506008148},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3351706266403198},{"id":"https://openalex.org/C43617362","wikidata":"https://www.wikidata.org/wiki/Q170050","display_name":"Chromatography","level":1,"score":0.3296964168548584},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.15688097476959229},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.12004649639129639},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001808","descriptor_name":"Blood Vessels","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006897","descriptor_name":"Hydroxyindoleacetic Acid","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000098","qualifier_name":"blood supply","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D017711","descriptor_name":"Nonlinear Dynamics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D044004","descriptor_name":"Xanthones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D044004","descriptor_name":"Xanthones","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D044004","descriptor_name":"Xanthones","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.ccr-07-1475","doi":"https://doi.org/10.1158/1078-0432.ccr-07-1475","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-07-1475","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:18381951","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18381951","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":35,"referenced_works":["https://openalex.org/W1492459972","https://openalex.org/W1494377166","https://openalex.org/W1659070396","https://openalex.org/W1975094435","https://openalex.org/W1984574841","https://openalex.org/W1985601808","https://openalex.org/W1987505695","https://openalex.org/W1987553146","https://openalex.org/W2010672987","https://openalex.org/W2016396157","https://openalex.org/W2032841298","https://openalex.org/W2040134200","https://openalex.org/W2061132293","https://openalex.org/W2062475006","https://openalex.org/W2066464642","https://openalex.org/W2069390709","https://openalex.org/W2070264211","https://openalex.org/W2071272749","https://openalex.org/W2076600611","https://openalex.org/W2078380224","https://openalex.org/W2091686839","https://openalex.org/W2093213782","https://openalex.org/W2100245381","https://openalex.org/W2119469074","https://openalex.org/W2121926322","https://openalex.org/W2128078652","https://openalex.org/W2130035135","https://openalex.org/W2140568954","https://openalex.org/W2153806861","https://openalex.org/W2155358182","https://openalex.org/W2156460167","https://openalex.org/W2167501156","https://openalex.org/W2338756568","https://openalex.org/W2412680383","https://openalex.org/W2430561772"],"related_works":["https://openalex.org/W2263241835","https://openalex.org/W2119469074","https://openalex.org/W2032841298","https://openalex.org/W2076600611","https://openalex.org/W2058010480","https://openalex.org/W2093213782","https://openalex.org/W2089816485","https://openalex.org/W4388845532","https://openalex.org/W4362560077","https://openalex.org/W1863869016"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"develop":[2],"a":[3,23,49,89,205,220],"population":[4,178],"pharmacokinetic-pharmacodynamic":[5],"(PK-PD)":[6],"model":[7,91],"that":[8],"defines":[9],"the":[10,26,107,112,117,173,191,223],"dose-concentration-effect":[11],"relationship":[12],"of":[13,29,60,109,111,165,190,225,228,241,252],"5,6-dimethylxanthenone-4-acetic":[14],"acid":[15,20],"(DMXAA),":[16],"using":[17],"plasma":[18,34,168,200],"5-hydroxyindole-3-acetic":[19],"(5-HIAA)":[21],"as":[22,48,219],"biomarker":[24],"for":[25,125,155,161,180,255],"antivascular":[27],"effect":[28,164],"DMXAA.":[30],"EXPERIMENTAL":[31],"DESIGN:":[32],"The":[33,65,163,213],"DMXAA":[35,46,82,166,199,226],"and":[36,67,101,116,135,144,157,183,194,237],"5-HIAA":[37,169,218],"concentration":[38],"data":[39,69],"were":[40,70,85,103,137,185],"obtained":[41],"from":[42],"124":[43],"patients":[44],"receiving":[45],"monotherapy":[47],"20-minute":[50],"i.v.":[51],"infusion":[52],"weekly":[53],"or":[54],"every":[55],"3":[56],"weeks":[57],"at":[58,129],"doses":[59,227,254],"6":[61],"to":[62,153,159,230,248],"4,900":[63],"mg/m(2).":[64],"PK":[66],"PD":[68],"analyzed":[71],"by":[72,88,172,204],"nonlinear":[73],"mixed":[74],"effects":[75],"modeling":[76],"with":[77,92,217],"NONMEM":[78],"version":[79],"5.":[80],"RESULTS:":[81],"concentration-time":[83],"profiles":[84],"well":[86],"described":[87,171],"three-compartment":[90],"saturable":[93,206],"elimination":[94,119,207],"(Michaelis-Menten":[95],"kinetics).":[96],"Body":[97],"surface":[98],"area":[99],"(BSA)":[100],"sex":[102],"significant":[104],"covariates":[105],"on":[106,167],"volume":[108],"distribution":[110],"central":[113],"compartment":[114],"(V(1))":[115],"maximum":[118],"rate":[120],"(V(m)),":[121],"respectively.":[122,197],"Population":[123],"estimates":[124,179],"V(m),":[126],"K(m)":[127],"(concentration":[128],"which":[130],"half":[131],"V(m)":[132,150],"is":[133,151,202,211],"achieved),":[134],"V(1)":[136],"112[1":[138],"+":[139],"0.474(2-sex)]":[140],"micromol/L/h,":[141],"102":[142],"micromol/L,":[143,187,196],"8.19(BSA/1.8)(0.857)":[145],"liters,":[146],"respectively":[147],"(sex":[148],"in":[149,233,250],"equal":[152,158],"1":[154],"males":[156],"2":[160],"females).":[162],"was":[170],"stimulatory":[174],"E(max)":[175],"model,":[176,216],"where":[177],"baseline,":[181],"E(max),":[182],"EC(50)":[184],"46.3":[186],"2.62-fold":[188],"increase":[189],"baseline":[192],"value,":[193],"631":[195],"CONCLUSIONS:":[198],"disposition":[201],"characterized":[203],"process.":[208],"BSA-guided":[209],"dosing":[210],"important.":[212],"present":[214],"PK-PD":[215,243],"biomarker,":[221],"supports":[222],"use":[224],"1,000":[229],"2,000":[231],"mg/m(2)":[232],"phase":[234,256],"II":[235,257],"studies,":[236],"provides":[238],"an":[239],"example":[240],"how":[242],"models":[244],"can":[245],"be":[246],"used":[247],"aid":[249],"selection":[251],"drug":[253],"evaluation.":[258]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":4},{"year":2015,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}